Clinical trials
RSV Infection clinical trials
Below are recruiting rsv infection clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07482657RecruitingPhase 2
Zelicapavir for RSV in infants and toddlers
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
BangkokAges 4 weeks–3 years - NCT06955728RecruitingPhase 3
RSV vaccine in pregnancy to protect babies
This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.
Kintampo, Bono EastAges 14–55 - NCT06881953Recruiting
Preventing RSV in infants in France
This trial studies ways to prevent RSV infections in newborns. If you are a parent who gave birth in France between October 2024 and January 2025, you may be able to help researchers learn how to better protect babies from RSV.
ParisAges 18 years+ - NCT06401720Enrolling by invitation
Flu immune response study by age
This study looks at how the immune system reacts to the flu in people of different ages. If you have flu symptoms and don't have cancer or take immune-suppressing drugs, you may be able to join.
SödertäljeAges 18 years+ - NCT07599449Recruiting
Tracking respiratory infections in French primary care
This study tracks viruses that cause sudden colds and flu-like illnesses during winter months in France. Researchers collect information from patients seen by participating doctors to better understand which respiratory viruses are circulating and help prepare for future outbreaks.
ParisAges Any age - NCT06998251Recruiting
Immune response to strep pneumonia in older adults
This study looks at how the immune system in the nose and throat reacts to Streptococcus pneumoniae bacteria and viruses in adults aged 60-85. It may help researchers find better ways to prevent or treat pneumonia.
GenevaAges 60–85 - NCT06172660Recruiting
RSV prevention study for babies in Connecticut
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
New Haven, ConnecticutAges Up to 1 year - NCT06197152Recruiting
RSV severity markers in hospitalized adults
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
CréteilAges 18 years+ - NCT07658534RecruitingPhase 2/Phase 3
Ziresovir for high-risk adults with RSV
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
Beijing, Beijing MunicipalityAges 18–85 - NCT06597916RecruitingPhase 2
RSV vaccine study for people with weakened immune systems
This study tests how well an RSV vaccine (Arexvy) works in people whose immune systems are weakened by certain cancers, autoimmune diseases, or treatments. It aims to see if the vaccine can protect these vulnerable groups from respiratory infections.
ViennaAges 18 years+ - NCT06775405RecruitingPhase 3
Testing a new RSV treatment for hospitalized babies
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
BeijingAges 1 month–2 years - NCT04743609Recruiting
Studying RSV illness impact in babies with ear or lung symptoms
This study looks at how RSV (a common virus that can affect breathing) leads to illness in young children who come to the doctor with ear infections and/or breathing symptoms. It may help doctors better understand the “burden” RSV causes in both home/outpatient and hospital settings.
CréteilAges 1 day–2 years - NCT06286007Recruiting
How whooping cough and RSV affect asthma in adults
This study looks at how infections like whooping cough and RSV impact asthma symptoms and control in adults. It aims to understand if these infections make asthma worse, which could help improve future treatment and prevention.
Santiago de Compostela, A CoruñaAges 18–99 - NCT07402512RecruitingPhase 3
Study of deuremidevir for RSV in infants and young children
This trial is testing a new medicine called deuremidevir for babies and young children with RSV infection. It is for those who have symptoms like fast breathing and wheezing, and have been sick for no more than 96 hours.
Xiamen, FujianAges 1 month–3 years - NCT07232706RecruitingPhase 3
RSV prevention in infants with nirsevimab and maternal vaccine
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
La Roche-sur-YonAges 18 years+ - NCT05045612RecruitingPhase 4
Antibiotics for certain viral lung infections in hospitalized adults
This trial studies whether giving antibiotics affects recovery in adults hospitalized with moderately severe infections caused by specific viruses (influenza, parainfluenza, RSV, or hMPV). It may help show when antibiotics are helpful or unnecessary for viral airway illness.
BergenAges 18 years+ - NCT06866405RecruitingPhase 3
RSV vaccine boost in a new pregnancy
This study tests whether a second dose of the RSV vaccine during a new pregnancy protects you and your baby from RSV. If you received the RSVpreF or Abrysvo vaccine in a past pregnancy, you may be able to join.
Birmingham, AlabamaAges birth+ - NCT06856967Recruiting
Nirsevimab for RSV in infants under 1 year
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
Arezzo, ArezzoAges Up to 1 year - NCT07640581Recruiting
RSV Infection Study in Babies Under 2 Years
This study tracks how respiratory syncytial virus (RSV)—a common respiratory infection in babies—affects children under 24 months in Ho Chi Minh City. Researchers want to understand how often RSV happens, how severe it is, and how it impacts families, so they can better prepare healthcare services.
Ho Chi Minh City, Ho Chi MinhAges birth–2 years - NCT06160128Recruiting
VA study on COVID-19 and medication effectiveness
This study looks at how well COVID-19 treatments work for veterans. It uses VA health records to see what medicines help and how people recover. You may be able to join if you are a veteran in VA care.
Portland, OregonAges 18 years+ - NCT06180993Recruiting
Nirsevimab for infants born in Galicia
This trial tests a preventive medicine called nirsevimab given to infants to see how well it protects them from a common serious lung infection. It is offered as part of regular check-ups for babies born during a specific time period.
Santiago de Compostela, A CoruñaAges 1 day–2 years - NCT06843317RecruitingPhase 1
RSV vaccine booster for older adults
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
Phoenix, ArizonaAges 60–85 - NCT05655182RecruitingPhase 1/Phase 2
RSV vaccine study for infants and toddlers who may be at risk
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
La Mesa, CaliforniaAges 6 months–5 years - NCT06817889RecruitingPhase 2
Remdesivir for RSV in people with weak immune systems
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
Duarte, CaliforniaAges 18 years+
Hear when a new RSV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rsv infection?
- Yes. Clin2 currently lists 32 recruiting rsv infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rsv infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rsv infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.